Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04454216 · ClinicalTrials.gov registry record
GSD VI and GSD IX Natural History
A clinical trial of Glycogen Storage Disease VI and GLYCOGEN STORAGE DISEASE IXa1, sponsored by Duke University.
- Recruiting
- Registry status
- 400
- Enrollment target
- 1
- Study location
NCT04454216: Recruiting study of Glycogen Storage Disease VI and GLYCOGEN STORAGE DISEASE IXa1, sponsored by Duke University.
NCT04454216 is a study of Glycogen Storage Disease VI and GLYCOGEN STORAGE DISEASE IXa1 that is actively recruiting participants, run by Duke University. The registered enrollment target is 400 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04454216, a study of Glycogen Storage Disease VI and GLYCOGEN STORAGE DISEASE IXa1, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
Collection and review of clinical information related to Glycogen Storage Disease Type VI (GSD VI) OR Glycogen Storage Disease Type IX (GSD IX) generated during clinic visits.
Conditions Studied
Interventions
- OTHER No intervention
Study Locations (1)
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2020-09-18 |
| Est. Completion | 2030-01-01 |
What NCT04454216 shows while recruiting
NCT04454216 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap.
The record links to 7 conditions, with Glycogen Storage Disease VI appearing as the primary indexed condition, and to 1 intervention - of which No intervention is the first listed.
NCT04454216 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT04454216 about?
NCT04454216 is a clinical study titled "GSD VI and GSD IX Natural History". Collection and review of clinical information related to Glycogen Storage Disease Type VI (GSD VI) OR Glycogen Storage Disease Type IX (GSD IX) generated during clinic visits.
What is the current status of trial NCT04454216?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2020-09-18. Estimated completion is 2030-01-01.
What conditions does trial NCT04454216 study?
This clinical trial studies the following conditions: Glycogen Storage Disease VI, GLYCOGEN STORAGE DISEASE IXa1, GLYCOGEN STORAGE DISEASE IXa2, Glycogen Storage Disease IXB, Glycogen Storage Disease IXC.
What interventions are being tested in trial NCT04454216?
The interventions under investigation include: No intervention (OTHER).
Who is sponsoring clinical trial NCT04454216?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04454216 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI